L’Assemblée populaire nationale chinoise dispose d’un cadre juridique pour des séances à huis clos. Le monde devrait y prêter attention.

Pour de nombreux observateurs extérieurs à la Chine, l’Assemblée populaire nationale (APN) est souvent considérée comme une assemblée législative purement cérémonielle. Pourtant, un aspect négligé de son cadre juridique mérite une attention internationale bien plus grande : l’APN est explicitement autorisée à tenir des séances à huis clos, tout en faisant simultanément passer ses documents de séance à un système électronique.

Pris séparément, aucun de ces dispositifs n’a rien d’exceptionnel. De nombreuses assemblées législatives dans le monde disposent de procédures pour traiter des informations classifiées. Toutefois, le système politique chinois diffère sur un point crucial : l’APN fonctionne au sein d’un État à parti unique dans lequel le Parti communiste chinois (PCC) exerce une direction sur le système politique, l’armée et le processus législatif. Ce contexte institutionnel modifie fondamentalement les implications, en matière de transparence et de responsabilité, des délibérations législatives secrètes.

Les séances à huis clos sont explicitement autorisées

L’article 19 du Règlement intérieur de l’Assemblée populaire nationale prévoit que l’APN peut convoquer des séances à huis clos « lorsque cela est nécessaire ». La décision est prise selon des procédures internes impliquant le Présidium, après consultation des chefs de délégation.

Cela signifie que le plus haut organe législatif de l’État chinois dispose d’un mécanisme juridique formel permettant que les délibérations se déroulent hors du regard du public.

Les documents législatifs sont en cours de numérisation complète

L’article 22 du même Règlement encourage la numérisation des documents de séance grâce aux technologies modernes de l’information.

Pris ensemble, ces dispositifs créent la possibilité que les documents liés aux séances à huis clos — y compris les ordres du jour, les rapports, les projets de décision, les notes d’information, les amendements et les documents internes de délibération — existent et circulent principalement sous forme électronique plutôt que sous la forme d’une documentation imprimée abondante.

La numérisation offre incontestablement des gains d’efficacité administrative. Toutefois, lorsqu’elle est combinée à des séances à huis clos légalement autorisées, elle peut aussi réduire la quantité de preuves documentaires accessibles au public pour les recherches historiques ultérieures, la vérification indépendante ou le contrôle institutionnel.

L’armée est directement représentée au sein de la législature

Une autre caractéristique distinctive de l’APN est l’existence d’une délégation distincte composée de représentants en service actif de l’Armée populaire de libération (APL).

Contrairement à de nombreuses législatures démocratiques où les forces armées ne participent pas au parlement en tant que bloc de vote, la délégation de l’APL constitue un élément institutionnel de l’APN elle-même.

Cela devient particulièrement pertinent chaque fois que la législation ou les décisions de l’État concernent la défense nationale, les affaires militaires, la sécurité nationale ou la mobilisation en temps de guerre.

Le secret est renforcé par le système chinois des secrets d’État

Le cadre juridique chinois comprend également un vaste régime des secrets d’État.

Si des informations discutées lors d’une séance à huis clos de l’APN sont classées comme secret d’État en vertu du droit chinois, leur divulgation non autorisée peut entraîner des responsabilités administratives, disciplinaires ou pénales.

Du point de vue des autorités chinoises, cela vise à protéger la sécurité nationale.

Du point de vue des observateurs extérieurs, cela signifie toutefois que la vérification indépendante de délibérations législatives importantes peut devenir extrêmement difficile.

Pourquoi cela importe au-delà de la Chine

L’importance internationale ne réside pas dans la simple existence de procédures législatives secrètes.

Elle réside plutôt dans la combinaison de plusieurs caractéristiques institutionnelles :

• Une législature légalement autorisée à tenir des séances à huis clos.
• Une dépendance croissante à l’égard d’une documentation législative exclusivement numérique.
• Une délégation dédiée de représentants militaires en service actif participant au sein de la législature.
• Un cadre juridique complet régissant les secrets d’État et les divulgations non autorisées.

Pris ensemble, ces éléments peuvent réduire la transparence du processus décisionnel législatif sur des questions susceptibles d’affecter non seulement la gouvernance intérieure de la Chine, mais aussi la sécurité régionale, la politique militaire, la concurrence technologique, la régulation économique et les relations internationales.

La transparence est un enjeu de sécurité mondiale

À mesure que l’influence de la Chine s’étend, les décisions prises par ses institutions législatives ont de plus en plus de conséquences bien au-delà de ses frontières.

Pour cette raison, les chercheurs, les journalistes, les décideurs publics, les archivistes et les organisations de défense des droits humains devraient accorder une attention plus soutenue non seulement aux résultats des décisions de l’APN, mais aussi aux processus institutionnels par lesquels ces décisions sont prises.

Comprendre ces processus — y compris l’autorisation légale des séances à huis clos, la numérisation des archives législatives et l’interaction entre le secret législatif et le système chinois des secrets d’État — est essentiel pour évaluer la transparence, la responsabilité et la gouvernance dans l’un des systèmes politiques les plus déterminants au monde.

La question n’est pas de savoir si chaque séance à huis clos dissimule une faute. La question est de savoir qu’une opacité institutionnelle limite le contrôle indépendant précisément au moment où les décisions peuvent avoir la plus grande portée publique.

Pour les gouvernements, les chercheurs et la société civile du monde entier, il s’agit là d’un défi en matière de transparence qui mérite une attention soutenue.

从444号决议到1776精神的回归：美国两党共识下的对中共共产主义列宁式组织的文明决战与历史总清算

长期以来，中文舆论场与跨国政论圈都深陷一个巨大的认知误区：他们习惯于将美中之间波涛汹涌的对抗，矮化为“川普个人的极端言论”或“MAGA运动的激进修辞”，将其娱乐化、戏剧化。甚至许多人天真地寄希望于通过“换个总统”或“等待某次中期选举”，就能让华盛顿重温旧梦。

这种浅薄的观察，完全忽略了美国整个国家机器——尤其是国会两党——在制度和法案层面的“深水静流”与彻底转向。

2026年的这个夏天，当美国迎来独立宣言250周年的历史性时刻，两场看似独立却内在逻辑高度统一的政治风暴正在华盛顿全面收网。一场是总统川普在总统山发表标志性演说，正式将“1776精神”拉升为清除共产主义的最高国家总动员战略；另一场则是美国参议院以全票一致的压倒性姿态，通过了由里克·斯科特（Rick Scott）发起的第444号决议（S.Res.444）。

这绝非一场关于关税或地缘排序的“修昔底德陷阱”争霸，而是一场跨越美国两党、结合国防建制（NDAA）与文明信仰的制度围堵和历史总清算。两代美国外交精英在经历了半个世纪被耍弄的痛苦后，终于将对华战车的方向盘彻底焊死。

Watch President Donald J. Trump's Full Speech on American Exceptionalism at Mount Rushmore on the eve of America's 250th: pic.twitter.com/vDmDFHQ3nj

— The White House (@WhiteHouse) July 4, 2026

一、 被耍弄的半个世纪：民主党“接触政策”的战略破产

要理解今天华盛顿那种两党内卷、不留退路的狠辣，就必须翻开冷战以来的外交账本。

历史上，正是美国民主党的建制派精英（从克林顿到奥巴马），极力推进了对华“接触政策”（Core Engagement）。然而到了2026年的今天，面对重返白宫并大打关税战的共和党政府，在野的民主党反而表现得更加歇斯底里——他们正在国会联合两党鹰派，利用更加精准的技术合规、金融审计和供应链防火墙，筑起阻击威权机器的“暗线防线”。

这种反差的背后，是民主党外交建制派历经半个世纪被耍弄后的战略清醒与制度性狂怒。

1. 朝鲜与越南：被选择性咽下的血债与列宁式的暴力基因

翻开《全国人大常委会公报》里第七届全国人大解放军代表团的官方履历，西方那些天真的外交官就会明白自己当年错得有多离谱：

• 在那个负责审批国家决算和财政报告的立法代表团里，堂而皇之地坐着柴云振（中华人民共和国中央人民政府在朝鲜半岛从事侵略并与联合国军交战的特等功臣）、秦基伟上将（中华人民共和国中央人民政府在朝鲜半岛从事侵略并与联合国军交战的上甘岭战役指挥官）、迟浩田上将（中华人民共和国中央人民政府在朝鲜半岛从事侵略并与联合国军交战的长津湖战役立功者）。

这构成了历史与法理的冰冷交织。1950年代的朝鲜战争，数万美军阵亡，中共在战后从未对其在朝鲜半岛从事侵略并与联合国军交战对抗美国做出过任何道歉；越南战场，北京高层亲自审查战役方案，更秘密派遣了超过32万中国军队（防空兵、工程兵）直接对美军作战。其中就包括当年在越南秘密拨付1000万美元和3个师装备消灭法军、从不道歉认错的韦国清上将。

当年以尼克松为代表的美国共和党现实主义政府为了地缘政治上“联华抗苏”的巨大实用主义利益，硬生生把这两口气咽了下去。华盛顿大度地选择历史“向前看”，却被列宁式组织视为“资产阶级纸老虎的软弱”——在这种纵容下，这个体制毫无顾忌地把这群“开枪者、花钱者、财政预算决算审批者三位一体”的幕后军头，堂而皇之地送上了自己全国人大的最高立法席位。

2. WTO与玫瑰园的完美出千：从“天真图章”到“暴力合规”

2001年，克林顿全力推动中国加入世贸组织（WTO），天真地认为经济自由必然带来政治民主；2015年，奥巴马在白宫玫瑰园听取了北京关于“南海绝不搞军事化”的公开承诺。

结果是毁灭性的。中共不仅反水将南海彻底军事化，更将这种“制度性欺骗”合法化地写进了地方和全国人大的最高议事程序中。

根据中共2026年3月主动公开的官方公告，新疆第十四届人大代表团里堂而皇之地坐着32名服从中央军委指挥的驻疆PLA和武警部队枪杆子人大代表。他们中既有代表全体新疆人去北京开会的内蒙古00后大兵丁晓杰，也有在2024年直接穿着军装高坐人大主席团、握有提案生杀大权与文官罢免权的军区司令员柳林中将。

这种“枪杆子卡死程序闸门”的真实面貌，直接让民主党的外交精英彻底抽醒：

• 在这个体制的字典里没有契约，只有兵不诈伪的拖延。当财政部监管局局长李若云等世俗文官，必须战战兢兢地跑去向握有空军通信权的米合伦沙·阿不都和境外押解警察赵金龙等全国人大代表“跪求认可”时，这就不是现代国家的预算审计，而是用暴力机器对文官系统执行“持枪合规”。

二、 参议院444号决议：全景式的罪状定性与道德海啸

2026年6月16日通过的第444号决议，其篇幅之长、细节之具体，堪称是一份对列宁式极权体制的“全面起诉书”。它不再使用温和的外交辞令，而是通过一长串冰冷的指控，彻底剥离了中共体制在西方眼中的合法性：

• 人道与公共卫生债： 决议直接将超过100万美国人因新冠疫情丧生的生命损失，归咎于中共初期的欺骗与隐瞒；同时痛斥其屡次跳票打击芬太尼的承诺，导致每年数万美国人死于毒品危机。

• 黑帮化的供应链： 决议甚至细致到了消费品安全领域，直接点名其违规使用人类排泄物作为肥料生产的“污水大蒜（sewage garlic）”及有毒消费品，向大众揭示其“在贸易中作弊”的骄傲传统。

• 踩碎文明底线的系统性性暴力： 最令国际社会震惊的，是决议首次在官方文本中使用了“东突厥斯坦（East Turkistan）”这一具有强烈政治历史意味的称谓，并盖棺定论地将其在当地实施的“结对认亲”政策定性为现代种族灭绝与危害人类罪。决议极其严肃地指控：国家力量在无限期关押维吾尔男子后，强迫留守的维吾尔人妻子与国家分配的男子同居、同床。

这种利用绝对行政权力剥夺女性身体自主权、用制度化手段摧毁家庭伦理的行径，彻底点燃了全美上下不分党派的道德怒火。

当维吾尔人的“民意”，被内蒙古00后大兵和立功警官‘代表’

当自由世界还在为参议院444号决议中揭露的“新疆结对认亲、强迫同床”感到文明世界彻骨的惊悚时，如果你翻开《新疆人大常委会公报》和官方新闻，就会发现这个体制在演戏方面的讽刺艺术已经达到了人类幽默史的巅峰。

在这里，“代表2000多万新疆人民”的政治皮影戏，已经连最起码的穿针引线都懒得做了。

根据2023年开启的第十四届新疆人大代表名单审计，代表团里堂而皇之地坐着32名服从中共中央军委指挥的驻疆解放军和武警部队“枪杆子代表”，以及核试验马兰基地所处的巴音郭楞蒙古自治州选出的30名代表。正是这群人在2023年1月18日举行的新疆人大第一次会议上，投票“选举”出了60名代表新疆的第十四届全国人大代表。

换句话说，在现代政治学上，所谓的“新疆民意代表”，其出生纸不仅需要中共党组织的审批，还必须经过中央军委指挥的现役军人用刺刀投出的赞成票。

到了2026年3月25日，新疆人大常委会更是发了一份“老实交待”的官方公告，对人大代表中枪杆子代表的来源供认不讳：宋伟军、丁晓杰、侯法武由新疆军区军人代表大会选出，闫倩由武警新疆总队军人代表大会选出。

这群由军人代表大会选出的立法者，天然背负着暴力机器的基因。比如代表新疆的丁晓杰，是一位2001年出生于内蒙古的00后中国人民解放军士兵，2019年成为喀什军分区电台值班见习员。按照宪法赋予人大代表的权力，这位00后现役战士在步入人民大会堂的那一刻，就合法变身为拥有修宪权、立法权和监督权的最高权力机关成员。一个在军营里参加比武竞赛的年轻士兵，在法理上成了决定2000多万新疆人乃至全中国十四亿人命运的“法定立法者”。

当西方和台湾的小清新还在用“橡皮图章”这种天真的词汇自我安慰，将人大主席台上的军装身影视为走过场的礼仪摆设时，中共自己的法律和议事规则早就把一记响亮的耳光甩在了他们的脸上。

如果严格按照《中华人民共和国全国人民代表大会议事规则》以及地方各级《人大组织法》中关于“主席团”的程序规定去审计，这群穿着军装、剃着平头高坐主席台上的军头，不仅是货真价实的立法者，更是掌握人大会议生死大权的最高程序判官。

2024年1月29日，新疆十四届人大第二次会议预备会议通过的主席团名单里，至少赫然列着3名中国人民解放军和武警部队的现役将军人大代表：杨诚、柳林和苏勇。中共中央广播电视总台CCTV及新疆卫视的视频画面清晰地展示了这一法理现场：在1月30日的开幕会议上，新疆军区政治委员杨诚、新疆军区司令员柳林中将、以及曾任武警新疆总队副参谋长的维稳先进个人苏勇，直接穿着笔挺的现役军装，大马金刀地坐在了主席台正上方。

在人大的议事规则中，主席团的权力到底有多大？它在现实性与法理上所拥有的双重有效特权，足以让任何现代宪政国家的法官惊出冷汗：

• 独揽提案与法案的“生杀大权”： 按照人大议事规则，任何普通代表团或代表联名提出的议案，能不能列入会议议程、能不能提交大会表决，唯一的决定权在主席团。也就是说，如果台下的世俗文官、地方法院或普通代表试图提出任何不符合中央意图的议案，柳林中将和杨诚政委坐在主席台上，不需要开枪，只需依法动用主席团的法定裁决权，就可以在程序上将其直接“枪毙”，使其连见光的可能都没有。

• 控制国家机关负责人的“提名与罢免权”： 根据法律，地方人大的各级政府官员、监察委主任、法院院长、检察院检察长的候选人，都是由主席团依法提出的；同时，主席团还握有向大会提出罢免这些官员的法定权力。当武警军头苏勇穿着军装作为主席团成员坐在上面时，台下坐着的各级文官系统、检察官和法官们心里非常清楚：上面坐着的不是普通网民所说的“花瓶”，而是掌控自己政治生命、能随时依法提名或罢免自己的“法定理事会董事”。

• 凌驾于司法与行政之上的“最高询问与质询权”： 在会议期间，主席团有权依法单方面决定延长会议时间，更有权随时召集各级政府官员、法院院长、检察院检察长前来汇报工作或接受询问。

当这种在法理上近乎无限的程序权力，与柳林中将手里的军区指挥权、苏勇武警首长手里的手铐与警棍完美结合时，所谓的“最高国家权力机关”就展现出了它最冰冷的真实面貌：这根本不是文官在开会，这是现役军头作为法定的主席团成员，在依照人大的法律程序，对整个地方法院、检察院和公务员系统进行居高临下的“暴力合规审计”。

2024年1月29日新疆14届人大第二次会议预备会议通过的主席团里面至少有3名中国人民解放军现役军人新疆人大代表，例如杨诚、柳林和苏勇。视频画面显示枪杆子新疆人大代表杨诚2024年1月30日穿军装坐在了新疆14届人大第二次会议开幕会议的主席台上。 https://t.co/OGXgWy4Gkl https://t.co/kShuwNOSHW pic.twitter.com/o3Byvrys8H

— CPA Jim (@CPAJim2021) June 29, 2026

同样穿着军装坐在主席台上的主席团成员，还有武警部队的代表苏勇。这位苏勇代表的履历更是黑色幽默的典范：2018年，他作为武警新疆总队副参谋长，因为在一线强力镇压而被表彰为“维稳工作先进个人”——也就是直接负责把新疆人送进集中营或高压管控的执行官。到了2025年1月19日的新疆十四届人大三次会议上，这位“先进个人”苏勇不仅依然是人大代表，胸前佩戴的标记和常年不变的寸头发型更是明确昭示着：他依旧是那个手握警棍与手铐的现役武警高级头目。一个负责把选民关起来的维稳军头，同时又是代表这些选民去立法的“主席团首长”，这种法理精神大概只有在精神病院里才能被理解。

在这个体制里，军队不仅负责台上的监军和台下的投票，甚至还公开插手少数民族地区的“人口定向清洗与改造”。担任新疆人大代表的现役军人孔祥宇上校，其真实身份是武警工程大学乌鲁木齐校区政治工作处主任。在2024年2月28日他率队赴西藏大学交流座谈时，这位“人大代表”就杀气腾腾地道出了真言：希望双方加强合作，共同为西部边疆少数民族地区培养一大批“靠得住、用得上、留得下”的军地两用复合型人才。翻译成现代反人类罪行的行业黑话就是：利用军警建制，加速对新疆、西藏少数民族进行文化换血和人口驯化，培养新一代的红色监工。

而在财政和预算监督领域，这种“持枪立法”的魔幻现实更被演绎得淋漓尽致。

根据中国财政部新疆监管局官方发布的报道，他们极其自豪地炫耀了新疆人大代表、财政部新疆监管局局长兼党组书记李若云，是如何向“枪杆子”和“刀把子”全国人大代表们汇报工作、悉心听取意见的。

在这场财政监管官员向暴力机器“跪求认可”的魔幻汇报中：

• 全国人大代表、空军驻新疆通信室主任米合伦沙·阿不都在认真听取汇报后，以最高立法者的姿态，对财政部服务代表的努力表达了“感谢”并给予“肯定”；

  
  
  

• 紧接着，财政监管局官员又满怀深情地走访慰问了全国人大代表、乌鲁木齐红庙子派出所便民警务站站长赵金龙警官——一位身穿刀把子制服、因为执行境外押解任务立了个人一等功的中共铁血鹰犬。这位“刀把子”代表，同样对财政工作给予了“充分肯定”。

  
  
  

一个原本应当代表选民捂紧钱袋子、严格审计军警开支的国家财政监督高官，居然要战战兢兢地跑去军营和派出所，向握着枪和手铐的“军代表、警代表”汇报工作，并因为得到这些暴力执行者的“认可与肯定”而欢欣鼓舞。在1776宪政文明的逻辑里，这叫“持枪抢劫国库”；但在列宁式的公报里，这叫“军民鱼水情、共商国是”。

这种“枪杆子”对立法的绝对碾压，在新疆人大代表、新疆军区陆军航空兵飞行员马凤龙身上完成了完美的逻辑闭环。马凤龙所在的陆航旅长年传承着一个30年不变的铁血信仰：

“操纵杆听我的话，我听党的话”；“手握操纵杆，铁心跟党飞”。

这就是中共中央、全国人大以及各大官方媒体主动公开的、具有最高法律效力的原生态中文证据。在这个体制里，不管是坐在主席台上的军区司令柳林中将，还是内蒙古00后电台兵丁晓杰，亦或是立了一等功的境外押解警察和手握武直操纵杆的飞行员。他们坐进最高立法殿堂的那一刻起，脑子里就没有“选民”和“法律”这两个词。他们的操纵杆、他们的枪托、以及他们按动人大表决器的手指，都只听从一个主人的大脑——那就是中共中央军委。

当西方和台湾的小清新还在指望通过与其“人大代表”进行法治交流来促进其政治文明时，中共自己的公报早就用这些穿着军装的主席团画面把答案扇在西方的脸上：我们的代表，从来不跟人民飞，只铁了心跟党飞。

三、 当1776宪政精神遇上“将军立法”的列宁式黑帮

为什么444号决议能在参议院获得两党毫无保留的全票通过？因为中共列宁式体制的底层结构，同时踩中了美国两党的文明死穴。

美国是一个深深建立在希伯来-基督教文明（Judeo-Christian tradition）与1776宪政基石上的国家。

• 在信仰层面： 身体是圣灵的殿，婚姻与家庭是神圣不可侵犯的契约。基督教十诫明确规定“不可奸淫”。任何强迫同床、系统性摧毁家庭细胞的行径，在基督教文明看来，都是地地道道的魔鬼行径。

• 在制度层面： 1776精神的底层逻辑是严格的文官治军与权力分立。在自由世界，现役军人绝不可干预文官立法。

然而，当年指挥越共的中共开国上将韦国清，其后的政治轨迹却是长期兼任全国人大常委会副委员长。这种“军队巨头、总政主任直接兼任国家最高立法机构领导人”的“党政军三位一体”结构，在西方眼中就是最典型的“持枪立法”和极权黑帮化统治。

1990年，当美国正沉浸在“历史的终结”、冷战即将胜利的虚幻自大中时，中国全国人大里的上甘岭指挥官们和戒严部队的将军们，却坐在一起，一边用暴力维护着国内的绝对统治，一边用按表决器的方式完成了对上一年军事行动消耗的自我审计。

中共《解放日报》的上观新闻网报道显示第七届全国人大常委会副委员长包括PLA军队代表韦国清、叶飞、廖汉生、乌兰夫、阿沛·阿旺晋美、赛福鼎，这届副委员长中有3位PLA上将、3位PLA中将。廖汉生是中国人民解放军军事科学院前政治委员。https://t.co/vC1ZHH2YEb pic.twitter.com/BUr5PDvMVU

— CPA Jim (@CPAJim2021) June 15, 2026

这种“拿过枪、开过火、杀过美军”的肉身实体，堂而皇之地坐在最高立法殿堂里担任代表，就是对现代西方宪政法理最具讽刺意味的挑衅。这也是为什么到了2026年，当两党翻完了这本写满欺骗与暴力的历史明细账后，华盛顿的共识会变得如此冰冷且充满杀机——因为任何理性的财务和制度审计都指向同一个结果：对一个由枪杆子监军、由昔日宿敌和暴力机器组成且从不进行真正权力分立的体制，唯一的应对方式不是对话，而是彻底的制度脱钩与文明对决。

正如博弈论的基本常识：你可以和对手谈利益，也可以和对手妥协价值观，但没人敢和桌子底下的“连环老千”继续玩下去。

当民主党发现自己追求的“绿色太阳能”背后深埋着强迫劳动的罪恶，发现自己退让的“国际多边秩序”成了对方吸血的工具时，这种被欺骗后的极度愤怒与羞耻感，促使他们与共和党并肩推起了制度的绞肉机。

四、 战略决战新阶段：1776精神的文明总动员

在立法院通过444号决议进行道德与建制定罪的同时，总统川普将独立宣言250周年提升为国家战略，正式完成了这场决战的政治拼图。

川普的战略逻辑大刀阔斧且清晰决绝：

1. 从利益博弈升华为信仰对决： 仅仅依靠关税和科技禁令，无法彻底瓦解一个控制了现代数字化监控手段的列宁式巨兽。必须用1776精神的核心奥义——“人权神授，任何世俗政权不得凌驾于个体的信仰和家庭之上”——作为解构共产主义的终极武器。

2. 身份的二选一： “你可以选择做马克思的门徒，也可以选择做美国的爱国者，但你绝不可能两者皆是。”这句重话不仅是对美国国内激进左翼的警告，更是向全球开辟了清晰的文明战线。

结语：方向盘已被焊死

历史走到2026年，美国对华的全面合围已经完成了底层代码的重写。

前台，是川普总统高亢的政治总动员，用“1776精神”凝聚海内外追求自由的力量；后台，则是两党在《国防授权法案》（NDAA）中细致到AI、半导体、网联汽车軟硬件、甚至生物基因和清洁能源供应链的冷酷切割。美国正在动用包括《全球马格尼茨基人权问责法》在内的所有金融与签证制裁工具，对这个反人类的极权组织进行人类历史上最严密的“制度净化”。

过去四十年由于西方的幼稚、纵容和地缘实用主义所养大的列宁式巨兽，终于迎来了它最无法逾越的文明长城。当1776精神的旗帜再度猎猎作响，这场推翻欺骗、捍卫尊严的战略决战，大幕已然轰然拉开，且绝无回头之路。

#Democracy #Christ #Peace #Freedom #Liberty #Humanrights #人权 #法治 #宪政 #独立审计 #司法独立 #独立自治

Yilin Cao, Harvard Medical School researcher, was winner of the Chinese National Science Fund for Distinguished Young Scholars, "Hundred Thousand Talents Project" National candidate engaged in 973 project

 Professor Cao Yilin, member of the Communist Party of China, chief physician, doctoral tutor, chief scientist of the national "973" project, distinguished professor of Changjiang Scholars, National Science Fund for Distinguished Young Scholars, young and middle-aged experts with outstanding contributions by the Ministry of Health, national labor model, Shanghai model labor. He graduated from the Department of Plastic Surgery of Shanghai Second Medical University in 1978, obtained a master's degree in 1988, and obtained a doctorate in the same year, under the tutelage of Professor Zhang Disheng, the founder of plastic surgery in China and an academician of the Chinese Academy of Engineering. In 1991, he won one of the two grants from the American Plastic Surgery Foundation with honors. He was engaged in postdoctoral research at Harvard Medical School in the United States, focusing on tissue engineering. He used to be the vice president of the Ninth People's Hospital Affiliated to Shanghai Jiaotong University School of Medicine. He is currently the director of the Shanghai National Engineering Research Center for Tissue Engineering, the director of the Shanghai Institute of Plastic Surgery, the director of the Shanghai Key Laboratory of Tissue Engineering, and the Shanghai Jiaotong University School of Medicine. Director of the Tissue Engineering Research Center, Associate Professor of the University of Massachusetts Medical School, Distinguished Professor of the Institute of Medical Molecular Biology, Kebangs ann University, Malaysia, Vice Chairman of the Asian Society of Tissue Engineering, Vice Chairman of the Chinese Biomaterials Committee, Chairman of the Chinese Medical Association Plastic Surgery Branch, Chairman of the Tissue Engineering Branch of the Chinese Society of Biomedical Engineering, vice-chairman of the Committee of Aesthetic and Plastic Physicians of the Chinese Medical Doctor Association, director of the Chinese Society of Biomedical Engineering, and member of the National Biomedical Materials Engineering Technology Committee. He is the editorial board member of two European publications, "British Journal of Plastic Surgery" and "Tissue Engineering" in the United States, editor-in-chief of "Chinese Journal of Plastic Surgery", executive deputy editor of the editorial board of "Journal of Plastic and Reconstructive Surgery", and "Journal of Shanghai Jiaotong University School of Medicine". Deputy Editor-in-Chief of the Editorial Board, Chief Medical Editor of Cosmetic Surgery Times, and Chinese Journal of Orthopaedic Trauma, Chinese Journal of Cranio-Maxillofacial Surgery, Chinese Journal of Modern Clinical Medicine, and Chinese Journal of Experimental Surgery ", "Chinese Journal of Practical Aesthetic Plastic Surgery", "Chinese Journal of Surgery" and other magazine editorial board. Won the title of "National Outstanding Scientific and Technological Worker of China Association for Science and Technology", "National Outstanding Professional Talent", "National Advanced Individual Honor for Returned Overseas Chinese and Relatives of Overseas Chinese", and "Returned Overseas Student Achievement Award". His personal results were awarded to James Barrett, American Plastic Surgeon Brown Award, the title of "National Outstanding Youth of the National Foundation for Distinguished Youth", the National Top Ten Science and Technology Innovation Awards of National Universities of the Ministry of Education, the title of "Qushi Science and Technology Foundation Outstanding Young Scholar", the title of "Shanghai Science and Technology Elite", and his scientific research achievements have won He has won 1 second prize of National Science and Technology Invention Award, 1 second prize of University Science and Technology Award, 1 second prize of China Medical Science and Technology Award, 1 third prize of China Medical Science and Technology Award, and 2 first prizes of Shanghai Science and Technology Progress Award , 2 second prizes, 1 second prize of Shanghai Science and Technology Achievement Award, 1 third prize of Shanghai Clinical Medical Achievement Award, and 1 Shanghai International Industry Fair Innovation Award. He has published more than 150 papers, edited 1, edited 1, participated in the preparation of 3 books, trained 6 postdoctoral fellows, 35 doctoral students, and 26 master students.

Cao Yilin, male, born in 1954, from Fengxian, Shanghai, chief physician, doctoral supervisor, chief scientist of the National Key Basic Research and Development Program (973) (two consecutive rounds), winner of the National Science Fund for Distinguished Young Scholars, "Hundred Thousand Talents Project" National candidate. He is currently the vice chairman of the Chinese Biomaterials Committee, the chairman of the Plastic Surgery Branch of the Chinese Medical Association, the chairman of the Tissue Engineering Branch of the Chinese Society of Biomedical Engineering, the vice chairman of the Chinese Medical Doctor Association Aesthetic and Plastic Surgery Branch Committee, and the vice chairman of the Chinese Society of Biomedical Engineering. He graduated from the Department of Plastic Surgery of Shanghai Second Medical University in 1978, obtained a master's degree in 1988, and obtained a doctorate in the same year. In 1991, he won one of the two grants from the American Plastic Surgery Foundation with honors. He was engaged in postdoctoral research at Harvard Medical School in the United States, focusing on tissue engineering.

　　During his master's and doctoral studies, Dr. Cao Yilin pioneered the surgical method of anastomotic nerve and free pectoralis minor muscle transplantation in China for the treatment of advanced facial paralysis. Appraised by experts, this achievement is the first in China and has reached the international advanced level. In 1991, he successfully performed in situ replantation of scalp avulsion wounds for the first time in China, and solved the permanent hair loss left by traditional treatment methods. Appraised by experts to reach the international advanced level. Prof. Cao Yilin's most outstanding contribution to human medicine is his great achievement in the field of tissue engineering research. For the first time in the world, tissue engineering technology was used to regenerate human auricle morphological cartilage in nude mice, thus demonstrating the application of tissue engineering technology to repair tissue for the first time. It caused a huge sensation in the international medical community, and the world's most famous plastic surgery "Plastic and Reconstructive Surgery" magazine published a special review, saying this achievement is a new milestone in the field of tissue engineering research. For this, he received the James Barrett Brown Award, the highest honor in the international plastic surgery community, the first person of Asian descent to receive this honor to date.

 

　　Cao Yilin has won the title of "Young and Middle-aged Expert with Outstanding Contributions from the Ministry of Personnel of the People's Republic of China", "National Outstanding Scientific and Technological Worker of China Association for Science and Technology", "National Outstanding Professional Talent", and "National Advanced Individual Honor for Returned Overseas Chinese and Relatives". "Achievement Award for Returnees from Studying Abroad" and National Model Worker and Model Worker in Shanghai. His personal achievements have won the title of "National Outstanding Youth of the National Foundation for Distinguished Youth", the title of "Outstanding Young Scholar of Qiushi Science and Technology Foundation", and the title of "Shanghai Science and Technology Elite". 1 second prize of China Medical Science and Technology Award, 1 third prize of China Medical Science and Technology Award, 2 first prizes and 2 second prizes of Shanghai Science and Technology Progress Award, 1 second prize of Shanghai Science and Technology Achievement Award, Shanghai 1 third prize of the Municipal Clinical Medical Achievement Award and 1 Innovation Award of the Shanghai International Industry Fair. He has published more than 270 papers (including nearly 50 SCI articles), edited 2 papers, translated 1 book, participated in the preparation of 3 books, trained 6 postdoctoral fellows, 40 doctoral students, and 27 master students.

Sheng Jiang, NCI/NIH researcher,returned to China at the end of 2007 and is now a researcher and doctoral supervisor of theCAS "Hundred Talents Program"

 Academic Report of Researcher Jiang Sheng, Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences

author:     Source: China Pharmaceutical University     Hits: 1563     Update Time: 2015-07-07

Report title : Discovery of Novel Class I Histone Deacetylase

Inhibitors through Total Synthesis of Natural Products

Report time : July 10 , 2015 (Friday) 9 :30-11:00

Location of the report: Lecture Hall 307 , Academic Exchange Center, Xuanwumen Campus

Speaker : Jiang Sheng, researcher, Chinese Academy of Sciences "Hundred Talents Program" researcher

Brief introduction : Jiang Sheng, Ph.D., researcher, graduated from China Pharmaceutical University in 1997 and 2000 with a bachelor's degree and a master's degree, respectively, and graduated from the Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences with a doctorate in 2003 . From 2003 to 2007 , he was engaged in postdoctoral research at the National Cancer Institute of the US Department of Health ( NCI/NIH ) and won the " NIH Fellows Award for Research Excellence ". He returned to China at the end of 2007 and is now a researcher and doctoral supervisor of the "Hundred Talents Program" of the Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences . He is also a member of the American Chemical Society, a member of the American Peptide Society, a member of the Chinese Chemical Society, and a senior member of the Chinese Pharmaceutical Association. The research group is mainly engaged in the research of total synthesis of natural products and medicinal chemistry. He has won the 973 project, the major project of "Major New Drug Creation Technology", and the National Natural Science Foundation of China.More than 10 scientific research projects . So far, more than 60 SCI papers have been published in internationally renowned journals such as Angew. Chem. Int. Ed. , J. Med. Chem. , J. Am. Chem.Soc , Org.Lett .

    All teachers and students are welcome to come!

                                       School of Pharmacy, Science and Technology Office

                                            July 7 , 2015 _ _

Jiang Sheng

announcer:Tao ShuyangViews:11101

Personal profiles:

Name :Jiang Sheng Gender :                  male      

Date of Birth :June 14 , 1976 _ _      Specialties : Medicinal Chemistry        

Education : Doctor of Science Professional Technical Position : Professor, Doctoral Supervisor           

E-mail : jiang_shengg @ 126.com    Telephone  (Tel.) : 18688888237

 

learning experience

1993 , 9-1997 , 7 : China Pharmaceutical University, Medicinal Chemistry, Bachelor 

1997 , 9-2000 , 7 : China Pharmaceutical University, Medicinal Chemistry, Master

2000 , 9-2003 , 7 : Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Organic Chemistry, Ph.D.

 

work experience

2003 , 11-2007 , 11 : National Institutes of Health ( NIH ) Cancer Institute ( NCI ); Medicinal Chemistry, Postdoc

2007 , 12-2016 , 12 : Guangzhou Institute of Biology and Health, Chinese Academy of Sciences, medicinal chemistry, doctoral supervisor ,Research group leader.

2017,1 - PRESENT : China Pharmaceutical University, medicinal chemistry, doctoral supervisor ,Research group leader.

 

Main academic achievements, scientific and technological achievements and innovations

 Dr. Jiang Sheng graduated from the Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences in 2003 with a Ph.D. in organic chemistry. From 2003 to 2007 , he worked as a postdoctoral researcher at the National Cancer Institute ( NCI/NIH ) of the U.S. Department of Health. After returning to China in 2008 , he served as a researcher and doctoral tutor of the "Hundred Talents Program" of Guangzhou Institute of Biomedicine and Health , Chinese Academy of Sciences .Research group leader . Now he is a doctoral supervisor of the Department of Medicinal Chemistry, China Pharmaceutical University .Research group leader. He is also a member of the American Chemical Society, a member of the American Peptide Society, a member of the Chinese Chemical Society, and a senior member of the Chinese Pharmaceutical Association. Employed for several international journals such as J. Med Chem. , Bioorg. Med. Chem. Lett. , Bioorg. Med. Chem. , Eur. J. Med Chem. ,  J. Org. Chem , Organic LettersSpecial reviewer for other journals, and review expert for projects such as the National Natural Science Foundation of China. In recent years, a total of 68 SCI papers have been published, including a series of innovative articles published in the international core journals Angew. Chem. Int. Ed., Organic Letters, Journal of Medicinal Chemistry and Journal of The American Chemical Society . Among them, " Rationally Designed Inhibitors Identify STAT3 N-Domain as a Promising Anticancer Drug Target " was published in the international publication ACS Chemical BiologyAfter it was published, it aroused strong interest from international peers and was selected as one of the most-accessed articles of the 1st quarter of 2008 .

  At the same time, research on the following projects was completed:

1.   Completed the design and synthesis of the anti-tumor natural product Annonaceous Acetogenins analogs. We used the natural annua lactone- Bullatacin as a template, simplified the double tetrahydrofuran ring into a ethylene glycol diether structure , retained its basic skeleton, and used the concepts of rational drug design, parallel synthesis, fragment assembly, etc. , to effectively establish annua lactone. A library of analog molecules with completely new chemical structures. Among them, the activity of compound AA019 on HT-29 tumor cells was 15 times that of doxorubicin , and it was not toxic to normal cells. In the in vitro test, the compound AA019 can effectively inhibit the growth of  lewis lung cancer in nude mice at an oral dose of 10 mg/kg (compared with the control group, the inhibition rate is more than 60% ). Currently, the compound is in preclinical studies. 

2.    Completed the design and synthesis of natural cyclic peptide ( SFTI-1 ) analogs. Using the binding model of SFTI-1 and protease, a series of novel cyclic peptides were successfully designed and synthesized by computer-aided drug design method. Among them, SFTI-15 had better proteolytic activity ( Ki = 10 nM ) and It has good selectivity and stability. Moreover, further in vivo and in vitro experiments showed that it can effectively inhibit tumor growth.

3.    Completed the design and synthesis of Grb2-SH2 polypeptide inhibitors. Taking G1TE as the lead, the design, synthesis and structure-activity relationship of G1TE analogs were systematically carried out . Among them , the activity of G177 on Grb2-SH2 is more than 1000 times that of G1TE . A batch of Grb2-SH2 antagonists with cell-level tumor growth inhibitory activity were also discovered during development, providing promising pharmacophore patterns and lead compounds for anti-tumor drug candidates.

4.   Completed the design and synthesis of cyclic peptide inhibitors of STAT-3 . This work was published in "ACS Chemical Biology" titled "Rationally Designed Inhibitors Identify STAT3 N-Domain as a Promising Anticancer Drug Target" and was named the most-accessed article of the first quarter of 2008 by ACS . 1st quarter of 2008 ).

5.   Participated in the University of Michigan as one of the main collaboratorsWang ShaomengProfessor presided over the new anti-tumor drug AT-101 , a broad-spectrum inhibitor of Bcl-2 family proteins, a Spirooxindole class of p53-MDM2 interaction blockers, isoflavone class Bcl-2 family protein inhibitors and protein IAP small molecule inhibitors, etc. Development of antineoplastic drugs.

6.   Completed the design and synthesis of selective inhibitors of histone deacetylation type I enzymes. Among them, the median inhibitory concentration ( IC50 ) of compound Lar-7 on tumor cell lines can reach as low as 1.0 nM ( 26 cell line experiments in vitro showed that the IC50 for multiple series of tumor cells was between 1-40 nM ), and the anti-tumor activity was A similar drug vorinostat ( SAHA ) has been listed abroad 10-100 times; and it is non-toxic to normal cells. The preliminary in vivo pharmacodynamic evaluation and acute toxicity evaluation of Lar-7 also reflect its low toxicity and high efficiency: it is resistant to human prostate cancer Du-145 , human breast cancer MDA-MB-231 and human leukemia imatinib Cells ( T315I ) subcutaneously transplanted tumor in nude mice had obvious inhibitory effect, and the relative tumor proliferation rates ( T/c% , Day-21 ) were 29.64% ,  20% and 37% , respectively . Preliminary acute toxicity test showed that the LD50 of Lar-7 in Kunming mice( 256.2 mg/kg ) is far greater than that of the similar drug Romidepsin ( 3.6 mg/kg ) that has been marketed abroad, showing extremely low toxicity. Currently, the compound is in preclinical studies.

7.   Design and synthesize a new biotin-labeled cyclic peptide compound , and successfully  " catch " a new protein  "r-catenin" with the labeled compound . We verified and found that this protein is a key protein in the self-renewal of leukemia cancer stem cells , and the compounds we designed can effectively overcome the problem of imatinib resistance by inhibiting this protein.

8.   Completed the design and synthesis of multiple inhibitors of EGFR, Her-2 and HDC . Among them, the median inhibitory concentration ( IC50 ) of compound JSNMPT-17 on multiple series of tumor cells is between 1-10 nM , and its anti-tumor activity is about 50 times that of a foreign phase II clinical drug ( CUC-101 ) . Currently , the in vivo pharmacodynamic evaluation of JSNMPT-17 is in progress.

9.   Completed the total synthesis of 7 natural products , they are Largazole, FK-228, Argyrins A and E, (-)-Norsecurinine, (+)-Niruroidine and Flueggine A.

10.  Completed the design and synthesis of IDO inhibitors. Among them, the antitumor activity of the compound JQIDO-003 is comparable to that of foreign phase II clinical drugs. Currently , the in vivo pharmacodynamic evaluation of  JQIDO-003 is ongoing.

 

Major scientific research projects hosted in the past five years

 

serial number	Subject name	Numbering	host or participate	Start and end time	expenses ( 10,000 yuan )	category
1	Synthesis of Compounds and Derivatives with Stem Cell Regulation Activity	2009CB940904	host	2009.1- 2013.12	6.9 million	973 project sub-topics
2	Study on the simplified analog AA-005 of annua lactone as an anticancer drug	2009ZX09103-101	host	2009.1- 2010 ．12	1.26 million	National New Drug Innovation Major Project
3	Structure-activity relationship and antitumor activity of histone deacetylase inhibitor Lar-7	21172220	host	2012.1- 2015.12	600,000 _	National Natural Science Foundation of China surface item
4	Total Synthesis of Argyrin A	20972160	host	2010.1- 2012.12	350,000 _	National Natural Science Foundation of China surface item
5	Proteolytic enzyme cyclic peptide inhibitor and its antitumor activity	20802078	host	2009.1- 2011.12	180,000 _	National Natural Science Foundation of China Youth Fund
6	Design and Synthesis of Cyclic Peptide Inhibitors of Proteolytic Enzymes	NNCAS-2008-8	host	2009.1- 2010 ．12	500,000 _	Novartis Nordisk - Chinese Academy of Sciences Joint Fund
7	Proteolytic enzyme inhibitors and their antitumor activity	KSCX2-YW-R-215	host	2010.1- 2010.12	200,000 _	Important direction project of knowledge innovation project of Chinese Academy of Sciences
8	Design and synthesis of small molecule inhibitors of proteolytic enzymes	8151066302000008	host	2009.1- 2011.12	50,000 _	Natural Science Foundation of Guangdong Province
9	Total Synthesis of Flueggines A and B	21472191	host	2015.1- 2018.12	900,000 _	National Natural Science Foundation of China surface item
10	Study on AA-005 as Anticancer Drug	2013A022100019	participate	2015.1- 2017.12	1.5 million	Guangdong Province New Drug Creation Project
11	Construction of Molecular Probes for Histone Deacetylation Type I Enzymes and Research on Early Diagnosis and Treatment	2016A050502036	host	2016.1- 2018.12	500,000 _	Guangdong Province International Cooperation Project
12	Molecular probes of histone deacetylation type I enzymes as early diagnosis and treatment of tumors		host	2017.5- 2020.4	1 million	Guangzhou Industry-University-Research Collaborative Innovation Major Project

 

Invited report

 

1. Sheng Jiang  (invited speaker), “Discovery of Novel Class I Histone Deacetylase Inhibitors through Total Synthesis of Natural Products”, National Cancer Institute 2015 (2015,10,20Fredercik, US).

2. Sheng Jiang  (invited speaker), “Discovery of Novel Class I Histone Deacetylase Inhibitors through Total Synthesis of Natural Products”, Chinese Pharmaceutical University 2015 (2015,7,10Nanjing, China).

2. Sheng Jiang  (invited speaker), "Discovery of Novel Class I Histone Deacetylase Inhibitors through Total Synthesis of Natural Products", The 4th Natural Product Total Synthesis - Youth Symposium (2015,7, Chengdu , China).

3.  Sheng Jiang  (invited speaker), "Discovery of Novel Class I Histone Deacetylase Inhibitors", 10th National Natural Organic Chemistry Conference of Chinese Chemical Society  (2014,11 Guangzhou, China).

4.  Sheng Jiang  (invited speaker), “Design, Synthesis and Biological Evaluation of Novel Class I Histone Deacetylase Inhibitors through Total Synthesis of Natural Products”, 2012 ( Shanghai , China).

5. Sheng Jiang  (invited speaker), “From Total Synthesis of Natural Products to Discovery of New Histone Deacetylase Inhibitors”, The 4th China-Thailand Workshop on Natural Products and Drug Discovery, Trang Province, Thailand, November 26-30, 2012

6. Sheng Jiang  (invited speaker), “Discovery of New Histone Deacetylase Inhibitors”, The 28th CCS National Congress (2012,Chendu, China)

7. Sheng Jiang  (invited speaker), “Design and synthesis New Histone Deacetylase 1 (HDAC1) inhibitors as potential anticancer drugs”, National Cancer Institute, Frederick, MD, 2010

8. Sheng Jiang  (invited speaker), “Total Synthesis of Largazole and its analogues potential anticaner drugs”, The 5 th  CCS National Congress on organic chemistry (2009, Xian,China).

9. Sheng Jiang  (invited speaker), “Potent antagonists of the Grb2-SH2 domain: Not relying on phosphotyrosine mimics”, Chinese Pharmaceutical University 2006 (2006,Nanjing, China).

 

10. Sheng Jiang ,  et al. “Potent antagonists of the Grb2-SH2 domain: Not relying on phosphotyrosine mimics”, 232 th  American Chemical Society Meeting (9/10-9/14, 2006).

11. Sheng Jiang ,  et al. “Synthesis and Evaluation of Analogs of SFTI-1, Potent Inhibitors of the Type II Transmembrane serine protease, Matriptase”, 230th American  Chemical Society Meeting (8/28-9/1, 2005).

12. Sheng Jiang ,  et al. “Synthesis of Symmetrical Dimeric Dicarboxylic Acid Linked Peptides on Solid support”, 19th American  Peptide Symposium (6/18-23, 2005).

13. Sheng Jiang , et al. “First Chemical Synthesis of Butenolide2", The 2 nd  CCS National Congress on organic chemistry and the 1 st  CCS National Congress on Chemical Biology (2002, China).

 

Awards and Honors:

2011  The 14th Chinese Pharmaceutical Association - Servier Youth Medicinal Chemistry Award

20 10     Hundred Talent Award

20 07 NIH Fellows award for the Research Excellence            

1996      Excellent Student  Scholarship

 

Patent

 

1.   “Synthesis and application of ether bond modified chiral annonaceous acetogenins compound”

Licensed to Shanghai Institute of Organic Chemistry

Inventors: ZJ Yao, YL Wu and S. Jiang.

Patent No. CN1477103

2.   “Method for synthesis of largazole and its analogs as antitumor agents.”

Inventors: S. Jiang, G. Zhou, B. Yin, X. Zeng, and Z. Hu.

Patent No. CN 101781321

3.  “Annonaceous acetogenins analogs as antitumor agents and their preparation, pharmaceutical compositions and use in the treatment of cancer”

Inventors:  S. Jiang,  ZJ Yao, G. Zhou, Q. Xiao, Y. Liu

Patent No. CN 101982464

4.   “Preparation of cyclopeptides as histone deacetylase inhibitors”

Inventors: S. Jiang,  S. Li, Y. Yao, F. Zhang, Y. Chao, H. Ye, M. Chen 

CN Patent Serial No. CN102391359

5.   “Preparation of triazole compounds as histone deacetylase inhibitors.”

Inventors: S. Jiang, Z.Tu, Y. Yao, C. Liu, H. Yao, X. Xue,

Patent No. CN 102311398

6.  “Process for preparation of FK228”

Inventors:  S. Jiang,  J. Xu, S. Li, H. Yao, X. Zeng,   Y. Yao,

Patent No. CN 102276689

7.        “Quinoxalinyl bis(N-oxide) derivatives and their application as ligands in Cu-catalyzed CO coupling reaction”

Inventors: Z. Yao,  S. Jiang, 

Patent No. CN 102060790

8.        “Quinoline derivative-N-oxide ligands, their preparation method and application in NC coupling”

Inventors:  Z. Yao,   S. Jiang, 

Patent No. CN 101899003

9.                  “Method for preparing epichlorohydrin tetramer and its reaction with   formaldehyde derivative”

      Inventors:  D. Zhang, J. Su, S. Jiang, 

Patent No. CN 103864727

10.    “Preparation of largazole analog compounds as antitumor agents”

      Inventors: S. Jiang,  Z. Tu, X. Li, Y. Yao, Y. Qiu

Patent No. CN 103601742

11.   “13-membered cyclic peptide as histone deacetylase inhibitor and its preparation”

    Inventors: H. Xiang, G. Wang, S. Jiang,  Z. Tu,

Patent No. CN 103232474

12.  "Preparation of N-containing heterocyclic derivatives as histone deacetylase I inhibitor"

Inventors: S. Jiang ,  Z. Tu, Q. Sun, C. Liu, Y. Yao, Y. Qiu,

Patent No. CN 103086971

13. “Preparation of 3-(pyridin-3-yl)acrylamide derivatives as nicotinamide phosphoribosyltransferase inhibitors useful for the treatment of cancer”

   Inventors: S. Jiang,  Z. Tu, D. Zheng, D. Qin, J. Bai, X. Qin, Y. Yao, Y. Liu, Y. Qiu, J. Chen

    Patent No. CN 104557863/PCT090572

 

  

 

Representative papers since engaging in scientific research

1.        J. Bai, , C. Liao, D. Qin, Y. Liu, X. Qing, J. Chen, Z. Li, Z. Tu, S. Jiang.* Structure-Based Design of Potent Nicotinamide Phosphoribosyltransferase Inhibitors with Promising In Vitro and in Vivo Antitumor Activities. J. Med. Chem . 2016 , 59 , 5766-5779.

2.       N. Ma, Y. Luo, Y. Wang, C. Liao, W.-C. Ye*, S. Jiang* .Selective histone deacetylase inhibitors with anticancer activity. Curr. Top. Med. Chem. 2016 , 16 , 415-426. 

3.       Y. Jin, Y. Yao, L. Chen, X. Zhu, B. Jin, Y. Shen, J. Li, X. Du, Y. Lu, S. Jiang* , J. Pan*.Depletion of γ-catenin by Histone Deacetylase Inhibition Confers Elimination of CML Stem Cells in Combination with imatinib.  Theranostics . 2016 , 6, 1947-1962.

4.       Y. Yao,Z. Tu,C. Liao, Z. Wang, S. Li, H. Yao, Z. Li, S. Jiang* .Discovery of Novel Class I Histone Deacetylase Inhibitors with Promising in Vitro Selectivity for Cancers Cells and in Vivo Antitumor Activities.  J. Med. Chem . 2015 , 58 , 7672-7680.

5.       Y. Yao,Z. Li, Y. Qiu, J. Su, S. Jiang* .Unprecedented reactions: from epichlorohydrin to epoxyglycidyl substituted divinyl ether and its conversion into epoxyglycidyl propargyl ether .  Scientific Reports .  2015, 5 , srep14231.

6.       N. Ma, Y. Wang, B. Zhao, W.-C. Ye*, S. Jiang* .The application of click chemistry in the synthesis of agents with anticancer activity. Drug Design, Development and Therapy . 2015 , 50 , 1585-1599. 

7.        J. Zhang, H. Zhou, S. Jiang,  J. Jin, W. Li, W. Wang, S. Su. AA092, an annonaceous acetogenin mimetic, attenuates angiogenesis in a mouse model of inflammation-induced corneal neovascularization. International Immunopharmacology . 2015 , 28 , 997-1002.

8.       Y. Zhou, G. Hou, S. He, Z. Xiao, H. Xu, Y. Qiu,S. Jiang, H. Zheng, Z. Li. Psora-4, a Kv1.3 Blocker, Enhances Differentiation and Maturation in Neural Progenitor Cells. CNS Neuroscience & Therapeutics . 2015 , 21 , 558-567.

9.       N. Ma, Y. Yao, B.-X. Zhao, Y. Wang, W.-C. Ye*, S. Jiang* .Total synthesis of securinega alkaloids (-)-norsecurinine, (-)-niruroidine and (-)-flueggine A. Chem. Commun . 2014 , 50 , 9284-9287. 

10.    X. Zhu, L. Chen, S. Jiang , C. Chen, Y. Yao, D. Chen, H. Xue, J. Pan * .PQJS380: a novel lead compound to induce apoptosis in acute lymphoblastic leukemia cells. Cancer Biology & Therapy . 2014 , 15 , 119-127. 

11.    J. Su, Y. Qiu, S. Jiang*,  D. Zhang*.New Ligands for Copper-Catalyst C[n.63743]N Coupling Reactions at Gentle Temperature. Chinese Journal of Chemistry . 2014 , 32(8) , 685-688.

12.    J. Su, Y. Qiu, K. Ma, Y. Yao, Z. Wang, X. Li, D. Zhang, Z. Tu, S. Jiang* .Design, synthesis, and biological evaluation of larga zole derivatives: alteration of the zinc-binding domain. Tetrahedron. 2014 , 70 , 7763-7769.

13.     H. Zhou, S. Jiang,  J. Chen, X. Ren, J. Jin, SB Su*. Largazole, an inhibitor of class I histone deacetylases, attenuates inflammatory corneal neovascularization. European Journal of Pharmacology. 2014 , 740 , 619-626.

14.    H. Zhou,S. Jiang,  J. Chen, SB Su*. Suberoylanilide hydroxamic acid suppresses inflammation-induced neovascularization.Can. J. Physiol. Pharmacol. 2014 , 92 , 879-885.

15.    Y. Liu, Y. Liu, Z. Liu, G. Zhou, Z.-J.Yao* , S. Jiang* . Identification of novel bivalent mimetics of annonaceous acetogenins via a scaffold-hopping strategy.  Bioorg. Med. Chem. Lett. 2014 , 24 , 1650-1653.

16.    Y. Liu, Q. Xiao, Y. Liu, Z. Li, Y. Qiu, G.-B. Zhou, Z.-J.Yao, S. Jiang* . Biological evaluation of new mimetics of annonaceous acetogenins: alteration of right scaffold by click linkage with aromatic functionalities. Eur. J. Med. Chem . 2014 , 78 , 248-258.

17.     Y. Yao, C. Liao, Z. Li, Z. Wang, Q. Sun, C. Liu, Z. Tu * , S. Jiang* . Design, Synthesis, and Biological Evaluation of 1, 3-Disubstituted- Pyrazole Derivatives as New Class I and IIb Histone Deacetylase Inhibitors.  Eur. J. Med. Chem . 2014 , 86 , 639-652. 

18.    Y. Zhao, X. Fang, Y. Wang, J. Zhang,  S. Jiang , Z. Liu, Z. Ma, L. Xu, E. Li, K. Zhang. Comprehensive Analysis for Histone Acetylation of Human Colon Cancer Cells Treated with a novel HDAC Inhibitor. Current Pharmaceutical Design . 2014 , 20 , 1866-1873.

19.     D. Zou, Y. Qiu, Z. Tu, C. Liao, J. Luo, Q. Meng, R. Yao, Z. Li, S. Jiang* .. Biological evaluation of 2-methylpyrimidine derivatives as active pan Bcr-Abl inhibitors. ScienceChina: Chemistry . 2014 , 57 , 823-832.

20.    Q. Meng, F. Li,S. Jiang, Z. Li*.Novel 64 Cu-labeled CUDC-101 for in vivo PET Imaging of histone deacetylases. ACS Medicinal Chemistry Letters . 2013 , 4, 858-862.

21.    L. Wu, Z. Wen, Y. Qiu, X. Chen, H. Chen, M. Wei, Z. Liu, S. Jiang*, G. Zhou*.Largazole arrests cell cycle at G1 phase and triggers proteasomal degradation of E2F1 in lung cancer cells; ACS Medicinal Chemistry Letters . 2013 , 4,  921-926.

22.    Y. Yao, H. Yao,S. Jiang*, X. Xue*.Progress in clinical study of histone deacetylase inhibitors as anticancer agents; Chinese J New Drugs . 2013 , 22  (3), 1-7.

23.    Q. Sun , Y. Yao,  C. Liu, H. Li, H. Yao, X. Xue, J. Liu, Z. Tu * , S. Jiang* . Design, Synthesis, and Biological Evaluation of Novel Histone Deacetylase 1 Inhibitors through click chemistry.  Bioorg. Med. Chem. Lett. 2013 , 23, 3295-3299.

24.    X. Li, Z. Tu, H. Li, C. Liu, Z. Li, Q. Sun, Y. Yao, J. Liu, S. Jiang* .Biological evaluation of new largazole analogues: Alteration of macrocyclic scaffold with Click chemistry; ACS Medicinal Chemistry Letters . 2013 , 4 , 132-136.

25.    Y. Qiu, W. Jia, Z. Yao, F. Wu, S. Jiang *. 2-Carbomethoxy-3-hydroxyquinoxaline-di- N - oxide as a novel ligand for the copper-catalyzed coupling reaction of phenols and aryl halides.  Organic & Biomolecular Chemistry. 2013 , 11, 1502-1510.

26.    Yang, Mei; He, Jiangbo; Cheng, Yongxian; Jiang, Sheng* . Synthesis of 3-[(Z)-pentadec-8-enyl]catechol and its anti-angiogenesis activity. Chinese Journal of Organic Chemistry . 2013 , 33(6), 1319-1325.

27.    D. Che, K. Yang, H. Xiang,S. Jiang* . New ligands for copper-catalyzed CN coupling reactions with aryl halides; Tetrahedron Letters . 2012 , 53, 7121-7124.

28.    Y. Liu, X. Cheng, L. Guo, C. Mao, Y. Chen, H. Liu, Q. Xiao, S. Jiang , Z. Yao, G. Zhou. Identification of an annonaceous acetogenin mimetic, AA005 , as an AMPK activator and autophagy inducer in colon cancer cells; PLoS One . 2012 , 7 , e47049.

29.    K. Su, Y. Qiu,; Y.Yao,; D. Zhang, S. Jiang* . 8-hydroxyquinolin-N-oxide-promoted copper-catalyzed CS cross-coupling of thiols with aryl iodides; Synlett . 2012 , 23, 2853-2857.

30.     Q. Xiao, Y. Liu, Y. Qiu, G. Zhou, C. Mao, Z. Li, Z.-J. Yao * , S. Jiang* . Potent Antitumor Mimetics of Annonaceous Acetogenins Embedded with an Aromatic Moiety in the Left Hydrocarbon Chain Part; J. Med. Chem. 2011 , 54 , 525-533.

31.    K. Yang, Y. Qiu, Z. Li, Z. Wang, S. Jiang* , Ligands for Copper-Catalyzed C-N Bond Forming Reactions with 1 Mol% CuBr as Catalyst.  J. Org. Chem , 2011 , 76, 3151-3159.

32.     Y. Qiu, Y. Liu, K. Yang, W. Hong, Z. Li, Z. Wang, S. Jiang*. New Ligands That Promote Cross-Coupling Reactions between Aryl Halides and Unactivated Arenes.  Org. Letters , 2011 , 13 , 3556-3559 .

33.     K. Yang, Z. Li, Z. Wang, S. Jiang* . Highly Efficient Synthesis of Phenols by Copper-Catalyzed Hydroxylation of Aryl Iodides, Bromides, and Chlorides.  Org. Letters , 2011 , 13, 4340-4343 .

34.     W. Wu, Z. Li, G. Zhou,  S. Jiang* . Total synthesis of argyrins A and E.  Tetrahedron. Lett . 2011 , 52 , 2488-2491.

35.    Z. Yao, X. Zeng, W. Yi,S. Jiang* . Stereoselective Synthesis of (S,E)-2-(trimethylsilyl)ethyl 3-hydroxy-7-(tritylthio) hept-4-enoate. Letters in Organic Chemistry, 2011 , 8 , 66-69.

36.    Q. Xiao, Y. Liu, Y. Qiu, Z. Yao, G. Zhou, Z.-J.Yao* , S. Jiang* . Design, synthesis of symmetrical bivalent mimetics of annonaceous acetogenins and their cytotoxicities.  Bioorg. Med. Chem. Lett. 2011 , 21 , 3613-3615.

37.     S. Li, H. Yao, J. Xu * , S. Jiang* . Synthetic Routes and Biological Evaluation of Largazole and Its Analogues as Potent Histone Deacetylase Inhibitors. Molecules , 2011 , 16 , 4681-4694.

38.    L. Johannessen, J.Remsberg, V. Gaponenko, KM Adams, JJ Barchi, SG Tarasov, S. Jiang ,   NI Tarasova. Peptide Structure Stabilization by Membrane Anchoring and its General Applicability to the Development of Potent Cell-Permeable Inhibitors. ChemBioChem. 2011 , 12 , 914- 921.

39.     Z. Yao, Y. Xu, M. Zhang, S. Jiang , MC Nicklaus, C. Liao. Discovery of a novel hybrid from finasteride and episteride as5a-reductase inhibitor.  Bioorg. Med. Chem. Lett, 2011 , 21 , 475-478.

40.    W. Hong, Y. Qiu, Z. Yao, Z. Wang,S. Jiang* . Palladium-Catalyzed Direct C–H Arylation of Unactivated Arenes with Aryl Halides.  Tetrahedron. Lett . 2011 , 52, 4916-4919.

41.    X. Zeng, W. Huang, Y. Qiu, S. Jiang *. Efficient Copper-Catalyzed Synthesis of Anilines by Employing Aqueous Ammonia.  Organic & Biomolecular Chemistry. 2011 , 9, 8224-8227.

42.    Y. Xu, F. Wu, Z. Yao, S. Jiang . Synthesis of quinoxaline 1,4-di-N-oxide analogues and crystal structure of 2-carbomethoxy-3-hydroxyquinoxaline-di-N-oxide. Molecules , 2011 ,  6894-6901 .

43.     X. Zeng, B. Yin, Z. Hu, C. Liao, Z. Li, G. Zhou*, S. Jiang * .Total Synthesis and Biological Evaluation of Largazole and Derivatives with Promising Selectivity for Cancers Cells.  Orgainc. Lett . 2010 , 12 , 1368-1371.

44.     J. Zheng, B. Yin, W. Huang, X. Li, H. Yao, Z. Liu, S. Jiang *. Efficient and selective cleavage of the t -butoxycarbonyl group from di- t -butylimidodicarbonate using catalytic bismuth (III) bromide in acetonitrile. Tetrahedron. Lett . 2009 , 50 , 5094-5097.

45.     S. Jiang* , C. Liao, L. Bindu, B. Yin, KW Worthy, RJ Fisher, TR Burke, Jr., MC Nicklaus, PP Roller. Discovery of thioether-bridged cyclic pentapeptides binding to Grb2-SH2 domain with high affinity. Bioorg. Med. Chem. Lett.2009 , 19 , 2693-2698.

46.    Z. Nikolovska-Coleska, J. Meagher, S. Jiang,  C. Yang, S. Qiu, PP Roller, J. Stuckey, S. Wang. Interaction of a Cyclic, Bivalent Smac Mimetic with the X-Linked Inhibitor of Apoptosis Protein. Biochemistry . 2008 , 47 , 9811-9824.

47.     S. Jiang *, Z. Li, K. Ding, PP Roller. Recent Progress of Synthetic Studies to Peptide and Peptidomimetic Cyclization. Current Organic Chemistry. 2008 , 12 , 1502-1542.

48.     Z. Nikolovska-Coleska, J. Meagher, S. Jiang, SA Kawamoto, W. Gao, H. Yi, D. Qin, PP Roller, J. Stuckey, S. Wang. Design and characterization of bivalent Smac-based peptides as antagonists of XIAP and development and validation of a fluorescence polarization assay for XIAP containing both BIR2 and BIR3 domains. Anal Biochem. 2008 , 374 , 87-98.

49.     OA Timofeeva, V. Gaponenko, SJ Lockett, SG Tarasov, S. Jiang , CJ Michejda, AO Perantoni, NI Tarasova. Rationally designed inhibitors identify STAT3 N-domain as a promising anticancer drug target.  ACS Chem Biol. 2007 , 2 , 799-809.

50.     S. Jiang, P. Li, SL Lee, CY Lin, YQ Long, MD Johnson, RB Dickson, PP Roller. Design and Synthesis of redox stable analogues of Sunflower Trypsin inhibitors (SFTI-1) on solid support, potent inhibitors of Matriptase. Orgainc. Lett . 2007 , 9 , 9-12 .

51.    HX. Liu, GR. Huang, HM Zhang, S. Jiang, J.-R. Wu, Z. -J. Yao.  A Structure-Activity Guided Strategy for Fluorescent Labeling of Annonaceous Acetogenin Mimetics and their Application in Cell Biology .ChemBioChem.2007 , 8 , 172-177.

52.     P. Li,  S. Jiang,  SL Lee, CY Lin, MD Johnson, CJ Michejda, RB Dickson, PP Roller.Synthesis and evaluation of analogs of SFTI-1, potent inhibitors of the Type II transmembrane serine protease, Matriptase. J. Med. Chem. 2007 , 50, 5976-5983.

53.    P. Li, S. Jiang,  PCStephanie, O. Lyn, DN Krag,PP Roller. Design and Synthesis of Water-Soluble Conjugates of Paclitaxel to Extracellular Doma in of ErbB2-Recognizing Peptide. Biopolymers. 2007 , 87,  225 -230.

54.    H. Sun, Z. Nikolovska-Coleska, J. Lu, J. Meagher, C. Yang, S. Qiu, Y. Tomita, Y. Ueda, S. Jiang,  Krajewski, PP Roller, JA Stuckey, S.Wang.Design, Synthesis and Characterization of A Potent, Non-Peptide, Cell-Permeable, Bivalent Smac Mimetic that Concurrently Targets both the BIR2 and BIR3 Domainsin XIAP. J. Am. Chem. Soc. 2007 , 129, 15279-15294. 

55.    GZ Tang, CY Yang, Z. Nikolovska-Coleska, J. Guo, S. Qiu, RX Wang, W. Gao, GP Wang, J. Stuckey, K. Krajewski, S. Jiang,  PP Roller, S. Wang .Pyrogallol-based molecules as potent inhibitors of the antiapoptotic Bcl-2 proteins.  J. Med. Chem.2007 , 50, 1723-1726.

56.    GZ Tang, K. Ding, Z. Nikolovska-Coleska, CY Yang, S. Qiu, S. Shangary, RX Wang, J. Guo, W. Gao, J. Meaghe, J. Stuckey, K. Krajewski, S . Jiang,  PP Roller, S. Wang.Structure-Based Design of Flavonoid Compounds As a New Class of Small-Molecule Inhibitors of the Anti-apoptotic Bcl-2 Proteins. J. Med. Chem.2007 , 50 , 3163-3166.

57.    J. Chen, Z. Nikolovska-Coleska, CY Yang, C. Gomez, W. Gao, K. Krajewski, S. Jiang , P.  P. Roller, S. Wang. Design and synthesis of a new, conformationally constrained , macrocyclic small-molecule inhibitor of STAT3 via 'click chemistry'.Bioorg. Med. Chem. Lett.2007 , 17 , 3939-3942.

58.     S. Jiang,  P. Li, CC Lai, JA Kelley,P. Roller.Design and Practical Synthesis of Fully Protected analogs of L-γ-Carboxyglutamic Acid.  J. Org. Chem. 2006 , 71 , 7307-7314.

59.     S. Jiang,  P. Li, M. Peach, RJ Fisher, TR Burke, M. Nicklaus, PP Roller. Structure-based design of potent Grb2-SH2 domain antagonists not relying on phosphotyrosine mimics.  Biochem. Biophys. Res. Commun. 2006 , 349 , 497-503.

60.     S. Jiang,  CC Lai, JA Kelley, PP Roller. A   Practical Synthesis of Fully Protected L-γ-Carboxyglutamic Acid (L-Gla).  Tetrahedron. Lett . 2006 , 47, 23-25.

61.    GP Wang,  Z. Nikolovska-Coleska, CY Yang, RX Wang, GZ Tang, J. Guo, S.    Shanggary, S. Qiu, W. Gao, DJ Yang, J. Meagher, J. Stuckey, K. Krajewski , S. Jiang,  PP Roller, HO Abbaan, Y. Tomita, S. Wang. Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins.  J. Med. Chem.2006 , 49, 6139-6142.

62.    Y. Zhao, S. Jiang,  YW Guo, Z.-J.Yao.  Synthesis of two naturally occurring 4-hydroxylated butenolides with PTP1B inhibitory activity. Chinese. J. Chem . 2005 , 23 , 173-175.

63.     S. Jiang , Y. Li, XG Chen, TS Hu, YL Wu, Z.-J. Yao. Parallel fragment assembly strategy towards multiple-ether mimicry of anticancer annonaceous acetogenins.  Angew. Chem. Int. Ed . 2004 , 43 , 329-334. 

64.    GR Huang, S. Jiang , YL Wu, ZJ Yao, JR Wu. Induction of cell death of gastric cancer cells by a modified compound of the annonaceous acetogenin family.  Chem BioChem 2003 , 4 , 1216-1221.

65.    BB Zeng, YK Wu, S. Jiang , Q. Yu, ZJ Yao, Z. Liu, H. Li, Y. Li, X. Chen, YL Wu. Studies on Mimicry of Naturally occuring Annonaceous Acetogenins: Non-THF Analogues Leading to Remarkable Selective Cytotoxicity Against Human Tumor cells.Chem. Eur. J. 2003 ,  9 , 282-290.

66.     S. Jiang , YL Wu, ZJ Yao. Synthesis of A Mimicking Hybrid of Annonaceous acetogenin with Steroid for considerable Antitumor Activity Investigation.Chinese J. Chem. 2002 , 20 , 1393-1400.

67.     S. Jiang , YL Wu, ZJ Yao.  First Synthesis of Mosquito larvicidal Butenolides I and II.  Chinese J. Chem. 2002 , 20 , 692-696.

68.        S. Jiang , Z. Liu, G. Sheng, BB Zeng, XG Cheng, YL Wu, ZJ Yao. Mimicking of Annonaceous Acetogenins: Enantionselective Synthesis of a (4R)-Hydroxy Analog Having Potent Antitumor Activity.  J. Org. Chem , 2002 , 67 , 3404-3408.

• guide students

Jiang Shengnan Han doctoral supervisor Guangzhou Institute of Biomedicine and Health
Email: jiang_sheng@gibh.ac.cn
Tel: 020-32015318
Mobile number:
Mailing address: No. 190 Kaiyuan Avenue, Luogang District, Guangzhou
Postcode : 510530

Research areas

1. Rational design, synthesis and structure-activity relationship research of active small molecules and polypeptide compounds targeting specific pathogenic genes.
2. Total synthesis of natural products with antitumor activity and discovery of new leading drugs.

Admissions Information

   

Admissions Major

100701 - Medicinal Chemistry

Admissions direction

Design and Synthesis of
Anticancer Drugs Design and Synthesis of Anticancer Drugs

Education background

   

Education

-- Postgraduate

Bachelor of Science

-- PhD

study abroad

2003, 11~ 2007, 11 National Cancer Institute, National Institutes of Health (NIH, NCI), Postdoctoral fellow

work experience

2007, 11 ~ present, Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences

Publication information

   

Published papers

(1) Total synthesis of argyrins A and E, Tetrahedron. Lett., 2011, corresponding author
(2) Design, synthesis of symmetrical bivalent mimetics of annonaceous acetogenins and their cytotoxicities, Bioorg. Med. Chem. Lett., 2011, corresponding author
(3) Potent Antitumor Mimetics of Annonaceous Acetogenins Embedded with an Aromatic Moiety in the Left Hydrocarbon Chain Part, J. Med. Chem, 2011, corresponding author
(4) Ligands for Copper Catalyzed CN Bond Forming Reactions with CuBr as Catalyst, J. Org Chem, 2011, corresponding author
(5) Synthetic Routes and Biological Evaluation of Largazole and Its Analogues as Potent Histone Deacetylase Inhibitors, Molecules, 2011, corresponding author
(6) New Ligands That Promote Cross-Coupling Reactions between Aryl Halides and Unactivated Arenes, Org. Letters, 2011, corresponding author
(7) Total Synthesis and Biological Evaluation of Largazole and Derivatives with Promising Selectivity for Cancers Cells, Organicc. Lett., 2010, corresponding author

Research activities

   

scientific research projects

Presided over the National Natural Science Foundation of China, the 973 sub-project, and the National New Drug Creation Major Project.

guide students

Currently guiding students

Xiao Qicai Master student 077901-Medicinal chemistry  

Wu Wenbin Postgraduate 077901-Medicinal Chemistry  

Liu Yanghan Postgraduate 077901-Medicinal Chemistry